JNJ

233.01

+1.03%↑

ISRG

478.71

-3.54%↓

ABT

108.96

-0.46%↓

RDY

13.8

+1.55%↑

NEOG

10.27

+0.39%↑

JNJ

233.01

+1.03%↑

ISRG

478.71

-3.54%↓

ABT

108.96

-0.46%↓

RDY

13.8

+1.55%↑

NEOG

10.27

+0.39%↑

JNJ

233.01

+1.03%↑

ISRG

478.71

-3.54%↓

ABT

108.96

-0.46%↓

RDY

13.8

+1.55%↑

NEOG

10.27

+0.39%↑

JNJ

233.01

+1.03%↑

ISRG

478.71

-3.54%↓

ABT

108.96

-0.46%↓

RDY

13.8

+1.55%↑

NEOG

10.27

+0.39%↑

JNJ

233.01

+1.03%↑

ISRG

478.71

-3.54%↓

ABT

108.96

-0.46%↓

RDY

13.8

+1.55%↑

NEOG

10.27

+0.39%↑

Search

CorMedix Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

8.12 -0.73

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

8.02

Max

8.33

Pagrindiniai rodikliai

By Trading Economics

Pajamos

89M

109M

Pardavimai

65M

104M

P/E

Sektoriaus vid.

3.697

90.422

Pelno marža

104.112

Darbuotojai

64

EBITDA

37M

57M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+74.42% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-03-24

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-224M

644M

Ankstesnė atidarymo kaina

8.85

Ankstesnė uždarymo kaina

8.12

Naujienos nuotaikos

By Acuity

66%

34%

312 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

CorMedix Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-03 23:11; UTC

Pagrindinės rinkos jėgos
Įsigijimai, susijungimai, perėmimai

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

2026-02-03 23:50; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-02-03 23:50; UTC

Rinkos pokalbiai

Nikkei May Decline After Hitting All-Time High -- Market Talk

2026-02-03 23:42; UTC

Rinkos pokalbiai

Gold Edges Lower on Possible Technical Correction -- Market Talk

2026-02-03 23:41; UTC

Įsigijimai, susijungimai, perėmimai

KKR Makes AI Play With $10.9B Asia Data-Center Deal

2026-02-03 23:38; UTC

Uždarbis

AMD Sales Climb on Help From Data-Center Business -- Update

2026-02-03 23:29; UTC

Įsigijimai, susijungimai, perėmimai

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

2026-02-03 23:27; UTC

Įsigijimai, susijungimai, perėmimai

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

2026-02-03 23:25; UTC

Įsigijimai, susijungimai, perėmimai

KKR-Consortium Expects Deal to Close by Early 2H of 2026

2026-02-03 23:23; UTC

Įsigijimai, susijungimai, perėmimai

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

2026-02-03 23:22; UTC

Įsigijimai, susijungimai, perėmimai

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

2026-02-03 23:19; UTC

Rinkos pokalbiai

Australia Gold Miners Tipped to Rally Higher -- Market Talk

2026-02-03 23:19; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-02-03 22:56; UTC

Pagrindinės rinkos jėgos
Įsigijimai, susijungimai, perėmimai

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

2026-02-03 22:40; UTC

Uždarbis

Amdocs Extends Collaboration With T-Mobile

2026-02-03 22:39; UTC

Uždarbis

Amdocs 1Q Adj EPS $1.81

2026-02-03 22:39; UTC

Uždarbis

Amdocs 1Q Rev $1.16B

2026-02-03 22:39; UTC

Uždarbis

Amdocs 1Q EPS $1.45 >

2026-02-03 22:38; UTC

Uždarbis

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

2026-02-03 22:30; UTC

Įsigijimai, susijungimai, perėmimai

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

2026-02-03 22:22; UTC

Įsigijimai, susijungimai, perėmimai

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

2026-02-03 22:14; UTC

Uždarbis

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

2026-02-03 22:13; UTC

Uždarbis

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

2026-02-03 22:12; UTC

Uždarbis

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

2026-02-03 22:10; UTC

Uždarbis

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

2026-02-03 22:10; UTC

Uždarbis

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

2026-02-03 22:10; UTC

Rinkos pokalbiai

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

2026-02-03 22:10; UTC

Uždarbis

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

2026-02-03 22:09; UTC

Uždarbis

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

2026-02-03 22:09; UTC

Uždarbis

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Akcijų palyginimas

Kainos pokytis

CorMedix Inc Prognozė

Kainos tikslas

By TipRanks

74.42% į viršų

12 mėnesių prognozė

Vidutinis 14.25 USD  74.42%

Aukščiausias 16 USD

Žemiausias 13 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines CorMedix Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

4

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

9.2 / N/APalaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

312 / 352 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę CorMedix Inc

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
help-icon Live chat